IBRANCE (Palbociclib) Approved in Europe

Options
Bestbird
Bestbird Member Posts: 2,818

Just a quick heads up that the European Commission has approved IBRANCE (Palbociclib) in combination with an aromatase inhibitor for the treatment of women with hormone receptor-positive, HER2 negative metastatic breast cancer.

The approval also covers the use of IBRANCE in combination with fulvestrant (Faslodex) for patients who have received prior endocrine therapy.

From: http://www.investing.com/news/stock-market-news/pfizer's-ibrance-ok'd-in-europe-for-breast-cancer-439506

Categories